CN102247368A - Compound acrivastine sustained release tablets, and preparation method thereof - Google Patents
Compound acrivastine sustained release tablets, and preparation method thereof Download PDFInfo
- Publication number
- CN102247368A CN102247368A CN 201110130629 CN201110130629A CN102247368A CN 102247368 A CN102247368 A CN 102247368A CN 201110130629 CN201110130629 CN 201110130629 CN 201110130629 A CN201110130629 A CN 201110130629A CN 102247368 A CN102247368 A CN 102247368A
- Authority
- CN
- China
- Prior art keywords
- acrivastine
- parts
- hydroxypropyl emthylcellulose
- slow releasing
- pseudoephedrine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003792 acrivastine Drugs 0.000 title claims abstract description 46
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000007939 sustained release tablet Substances 0.000 title abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 16
- 239000008101 lactose Substances 0.000 claims abstract description 15
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims abstract description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims abstract description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000007779 soft material Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- -1 Hydroxypropyl Chemical group 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229960001375 lactose Drugs 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 3
- 238000004080 punching Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 abstract description 43
- 239000000463 material Substances 0.000 abstract description 10
- SQXPPECBPHSOSQ-GNWPWZHSSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;(e)-3-[6-[(e)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid;hydrochloride Chemical compound Cl.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 SQXPPECBPHSOSQ-GNWPWZHSSA-N 0.000 abstract description 4
- 239000000314 lubricant Substances 0.000 abstract description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 3
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 229910052681 coesite Inorganic materials 0.000 abstract 1
- 229910052906 cristobalite Inorganic materials 0.000 abstract 1
- 229910052682 stishovite Inorganic materials 0.000 abstract 1
- 229910052905 tridymite Inorganic materials 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- HDLOXDDMKWEDCR-PASALVRNSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;(e)-3-[6-[(e)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 HDLOXDDMKWEDCR-PASALVRNSA-N 0.000 description 1
- ZOPQOWMEWBFVAR-PXRPMCEGSA-N 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;(1s,2s)-2-(methylamino)-1-phenylpropan-1-ol Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZOPQOWMEWBFVAR-PXRPMCEGSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229940042500 acrivastine / pseudoephedrine Drugs 0.000 description 1
- 229940086148 acrivastine 8 mg Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940056152 cetirizine / pseudoephedrine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- ZQBWEJQBVWJHRY-PXRPMCEGSA-N ethyl 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carboxylate;(1s,2s)-2-(methylamino)-1-phenylpropan-1-ol Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 ZQBWEJQBVWJHRY-PXRPMCEGSA-N 0.000 description 1
- 229940042366 fexofenadine / pseudoephedrine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940033996 loratadine / pseudoephedrine Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940035056 pseudoephedrine hydrochloride 120 mg Drugs 0.000 description 1
- 150000003233 pyrroles Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 229940115174 semprex-d Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Images
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110130629 CN102247368B (en) | 2011-05-19 | 2011-05-19 | Compound acrivastine sustained release tablets, and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110130629 CN102247368B (en) | 2011-05-19 | 2011-05-19 | Compound acrivastine sustained release tablets, and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102247368A true CN102247368A (en) | 2011-11-23 |
CN102247368B CN102247368B (en) | 2013-05-29 |
Family
ID=44975175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110130629 Active CN102247368B (en) | 2011-05-19 | 2011-05-19 | Compound acrivastine sustained release tablets, and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102247368B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108125924A (en) * | 2018-03-16 | 2018-06-08 | 重庆华邦制药有限公司 | Acrivastine capsule and preparation method thereof |
US10874616B2 (en) | 2012-11-15 | 2020-12-29 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11045421B2 (en) | 2013-08-07 | 2021-06-29 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US11214573B2 (en) | 2011-06-20 | 2022-01-04 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US11285140B2 (en) | 2010-03-10 | 2022-03-29 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US11331320B2 (en) | 2005-12-13 | 2022-05-17 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1125396A (en) * | 1993-06-14 | 1996-06-26 | 詹森药业有限公司 | Extended release, film-coated tablet of astemizole and pseudoephedrine |
WO2002043706A2 (en) * | 2000-12-01 | 2002-06-06 | Labopharm Inc. | Prolamin-based sustained-release compositions and delayed-onset compositions |
CN1535686A (en) * | 2003-04-09 | 2004-10-13 | 北京德众万全药物技术开发有限公司 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
JP2009007332A (en) * | 2007-05-25 | 2009-01-15 | Daiichi Sankyo Healthcare Co Ltd | Pharmaceutical composition containing azelastines and ephedorines |
JP2010180238A (en) * | 2001-11-22 | 2010-08-19 | Daiichi Sankyo Healthcare Co Ltd | Composition for rhinitis |
WO2010140111A1 (en) * | 2009-06-02 | 2010-12-09 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a combination of an antihistamine and a decongestant |
-
2011
- 2011-05-19 CN CN 201110130629 patent/CN102247368B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1125396A (en) * | 1993-06-14 | 1996-06-26 | 詹森药业有限公司 | Extended release, film-coated tablet of astemizole and pseudoephedrine |
WO2002043706A2 (en) * | 2000-12-01 | 2002-06-06 | Labopharm Inc. | Prolamin-based sustained-release compositions and delayed-onset compositions |
JP2010180238A (en) * | 2001-11-22 | 2010-08-19 | Daiichi Sankyo Healthcare Co Ltd | Composition for rhinitis |
CN1535686A (en) * | 2003-04-09 | 2004-10-13 | 北京德众万全药物技术开发有限公司 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
JP2009007332A (en) * | 2007-05-25 | 2009-01-15 | Daiichi Sankyo Healthcare Co Ltd | Pharmaceutical composition containing azelastines and ephedorines |
WO2010140111A1 (en) * | 2009-06-02 | 2010-12-09 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a combination of an antihistamine and a decongestant |
Non-Patent Citations (1)
Title |
---|
《Journal of Pharmaceutical and Biomedical Analysis》 2005 Xiaochen Gu, et al. Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography 663-667 1-3 第37卷, * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11331320B2 (en) | 2005-12-13 | 2022-05-17 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US11744832B2 (en) | 2005-12-13 | 2023-09-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US11285140B2 (en) | 2010-03-10 | 2022-03-29 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US11214573B2 (en) | 2011-06-20 | 2022-01-04 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US10874616B2 (en) | 2012-11-15 | 2020-12-29 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11337927B2 (en) | 2012-11-15 | 2022-05-24 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US11576865B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11576864B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11896717B2 (en) | 2012-11-15 | 2024-02-13 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US11045421B2 (en) | 2013-08-07 | 2021-06-29 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
CN108125924A (en) * | 2018-03-16 | 2018-06-08 | 重庆华邦制药有限公司 | Acrivastine capsule and preparation method thereof |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Also Published As
Publication number | Publication date |
---|---|
CN102247368B (en) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102247368B (en) | Compound acrivastine sustained release tablets, and preparation method thereof | |
CN101695480B (en) | Olopatadine hydrochloride dispersible tablets, preparation method thereof and quality control method thereof | |
KR101977785B1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
CN101273973B (en) | Pharmaceutical combination containing Mosapride citrate | |
CN102988993A (en) | Screening and composition of main auxiliary materials of compound acetaminophen tablet, and preparation method of compound acetaminophen tablet | |
CN110403911A (en) | A kind of isosorbide mononitrate sustained release tablets and preparation method thereof | |
CN112220770B (en) | Pharmaceutical composition of selepag and preparation method thereof | |
CN114288257A (en) | Fluvoxamine maleate tablet and preparation method thereof | |
KR20010020163A (en) | Stabilized tibolone compositions | |
CN110420192A (en) | A kind of isosorbide mononitrate sustained release tablets and preparation method | |
CN103610677A (en) | Repaglinide troche and preparation method thereof | |
CN101966164A (en) | Nifedipine sustained release tablet | |
CN103356498B (en) | Mosapride citrate sustained-release tablet | |
CN103385876B (en) | Pharmaceutical composition of a kind of Frova and preparation method thereof | |
CN107753455B (en) | A tablet containing imidafenacin and its preparation method | |
CN102846625A (en) | Stable valsartan, amlodipine and hydrochlorothiazide pharmaceutical composition and preparation method thereof | |
CN106924237B (en) | It is a kind of containing En Gelie is net and the pharmaceutical composition of Metformin hydrochloride | |
CN102764254B (en) | A kind of levetiracetam medicinal composition and preparation method thereof | |
CN102240270B (en) | Blonanserin tablet and preparation method thereof | |
CN111773191A (en) | Compound solid preparation containing phenylephrine hydrochloride and preparation method thereof | |
CN102657628A (en) | Medicinal composition containing simvastatin and preparation method thereof | |
CN102379855A (en) | Glimepiride dispersible tablet and preparation method thereof | |
CN102389404B (en) | Desloratadine medicament compound | |
CN112704668B (en) | Pramipexole dihydrochloride sustained-release composition | |
CN102988372A (en) | Screening and composition of main auxiliary materials of compound aspirin tablet, and preparation method of compound aspirin sheet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound acrivastine sustained release tablets, and preparation method thereof Effective date of registration: 20160906 Granted publication date: 20130529 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2016340000050 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180612 Granted publication date: 20130529 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2016340000050 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound acrivastine sustained release tablets, and preparation method thereof Effective date of registration: 20180622 Granted publication date: 20130529 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018340000247 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound acrivastine sustained release tablets, and preparation method thereof Effective date of registration: 20200622 Granted publication date: 20130529 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003313 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200604 Granted publication date: 20130529 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018340000247 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211229 Granted publication date: 20130529 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003313 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a compound Avastin sustained release tablet and a preparation method thereof Effective date of registration: 20211230 Granted publication date: 20130529 Pledgee: Anhui Linquan rural commercial bank Limited by Share Ltd. Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980017339 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230613 Granted publication date: 20130529 Pledgee: Anhui Linquan rural commercial bank Limited by Share Ltd. Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980017339 |